title: Lipopolysaccharide inhibits ghrelin-excited neurons of the arcuate nucleus and reduces food intake via central nitric oxide signaling.
abstract: Lipopolysaccharide (LPS) induces anorexia and expression of inducible nitric oxide synthase (iNOS) in the hypothalamic arcuate nucleus (Arc). Peripheral administration of the iNOS inhibitor 1400 W counteracts the anorectic effects of LPS. Here we investigated the role of central NO signaling in LPS anorexia. In electrophysiological studies we tested whether 1400 W counteracts the iNOS-dependent inhibition of Arc neurons triggered by in vivo or in vitro stimulation with LPS. We used the hormone ghrelin as a functional reference stimulus because ghrelin is known to activate orexigenic Arc neurons. Further, we investigated whether in vitro LPS stimulation induces an iNOS-mediated formation of the second messenger cGMP. Since the STAT1 pathway contributes to the regulation of iNOS expression we investigated whether LPS treatment induces STAT1 phosphorylation in the Arc. Finally we tested the effect of intracerebroventricular injection of 1400 W on LPS-induced anorexia. Superfusion with 1400 W (10(-4) M) increased neuronal activity in 37% of neurons in Arc slices from LPS treated (100 μg/kg ip) but not from saline treated rats. Similarly, 1400 W excited 45% of Arc neurons after in vitro stimulation with LPS (100 ng/ml). In both approaches, a considerable percentage of 1400 W sensitive neurons were excited by ghrelin (10(-8)M; 50% and 75%, respectively). In vitro stimulation with LPS induced cGMP formation in the Arc, which was blocked by co-incubation with 1400 W. LPS treatment elicited a pSTAT1 response in the Arc of mice. Central 1400 W injection (4 μg/rat) attenuated LPS-induced anorexia and counteracted the LPS-dependent decrease in respiratory quotient and energy expenditure. In conclusion, the current findings substantiate a role of central iNOS dependent NO formation in LPS-induced effects on eating and energy homeostasis. A pharmacological blockade of NO formation might be a therapeutic approach to ameliorate disease-related anorexia.
authors.affiliation: Institute of Veterinary Physiology and Centre of Integrative Human Physiology, University of Zurich, 8057 Zurich, Switzerland.
authors.forename: Tito
authors.initials: T
authors.lastname: Borner
authors.forename: Sarah
authors.initials: S
authors.lastname: Pinkernell
authors.forename: Thomas A
authors.initials: TA
authors.lastname: Lutz
authors.forename: Thomas
authors.initials: T
authors.lastname: Riediger
mesh_terms: D000578:Amidines / Q000008:administration & dosage / Q000494:pharmacology*; D000818:Animals; D000855:Anorexia / Q000139:chemically induced / Q000523:psychology; D001111:Arcuate Nucleus of Hypothalamus / Q000166:cytology* / Q000187:drug effects* / Q000378:metabolism; D001596:Benzylamines / Q000008:administration & dosage / Q000494:pharmacology*; D006152:Cyclic GMP / Q000096:biosynthesis; D004435:Eating / Q000187:drug effects*; D055724:Electrophysiological Phenomena; D004791:Enzyme Inhibitors / Q000008:administration & dosage / Q000494:pharmacology*; D054439:Ghrelin / Q000037:antagonists & inhibitors* / Q000494:pharmacology*; D007150:Immunohistochemistry; D007276:Injections, Intraventricular; D008070:Lipopolysaccharides / Q000494:pharmacology*; D008297:Male; D009474:Neurons / Q000187:drug effects* / Q000378:metabolism; D009569:Nitric Oxide / Q000502:physiology*; D052247:Nitric Oxide Synthase Type II / Q000037:antagonists & inhibitors; D010766:Phosphorylation; D051381:Rats; D017208:Rats, Wistar; D050794:STAT1 Transcription Factor / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects*
chemical_list: D000578:Amidines; D001596:Benzylamines; D004791:Enzyme Inhibitors; D054439:Ghrelin; D008070:Lipopolysaccharides; C104820:N-(3-(aminomethyl)benzyl)acetamidine; D050794:STAT1 Transcription Factor; C494081:Stat1 protein, rat; D009569:Nitric Oxide; D052247:Nitric Oxide Synthase Type II; D006152:Cyclic GMP